USE OF MAPROTILINE IN THE TREATMENT OF AUTONOMIC DYSREGULATION WITH SYMPATHETIC DEFICIENCY

摘要

The present invention relates to medicine. The invention describes a novel use of Maproptiline in a daily dose of 25 to 75 mg in the treatment of autonomic dysregulation with sympathetic deficiency and, more specifically, symptomatic dysautonomic bradycardia subsequent either to vagal hyperactivity or to sympathetic deficiency. The anticholinergic effect of the molecule can be used to reduce the exaggerated vagal response to vagal stimulation tests. The invention provides a new pharmacological means for the treatment of autonomic dysregulation with sympathetic deficiency, with the added benefit of increasing the heart rate.